Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Beijing Surgerii Robotics has commercialized the first NMPA-cleared endoscopic single-port surgical robot in China for urological and gynecological procedures. The company’s “Shurui” platform offers advanced dexterity via a patented dual-continuum mechanism with superelastic nitinol rods. It enables three robotic arms through a single incision with enhanced flexibility compared to traditional multiport systems. Clinical use includes successful remote telesurgery between continents. The company collaborates with top hospitals to expand clinical indications into cardiothoracic and general surgeries while developing next-generation platforms such as cardiac-specific robots and NOTES solutions.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Beijing Surgerii Robotics.